Treating and preventing no reflow in the cardiac catheterization laboratory

Current Cardiology Reviews

Volumn 8, Issue 3, 2012, Pages 209-214

  Berg, Ryan ^a   Buhari, Cyrus ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenosine; Aspiration thrombectomy; Distal protection; Nitroprusside; No reflow; Verapamil

Indexed keywords

ABCIXIMAB; ADENOSINE; ALTEPLASE; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; NICARDIPINE; NITROPRUSSIDE SODIUM; PLACEBO; STREPTOKINASE; TIROFIBAN; VERAPAMIL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOPLASTY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CORONARY ARTERY BLOOD FLOW; DYSPNEA; FIBRINOLYTIC THERAPY; FLUSHING; HEART BLOCK; HEART CATHETERIZATION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HUMAN; HYPOTENSION; INTRACORONARY INFUSION; MECHANICAL THROMBECTOMY; MICROCIRCULATION; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEOLYTIC THROMBECTOMY; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; THROMBOSIS; THROMBUS ASPIRATION; VASODILATATION;

HUMANS; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBECTOMY; VASODILATOR AGENTS;

EID: 84870259305     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340312803217148     Document Type: Article

References (32)

1. Lee CH, Wong HB, Tan HC, et al. Impact of reversibility of no reflow phenomenonon 30-day mortality following percutaneous revascularizationfor acute myocardial infarction-insights from a 1,328patient registry. J Interv Cardiol 2005; 18: 261-266.
2. Levine GN, Bates ER, Blakenship JC et al. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am Coll Cardiol 2011; 58: e44-e122.
3. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-9.
4. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: theAcute Myocardial Infarction STudy of ADenosine (AMISTAD)trial. J Am Coll Cardiol 1999; 34: 1711-20.
5. Ross AM, Gibbons RJ, Stone GW, et al. AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct toreperfusion in the treatment of acute myocardial infarction(AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.
6. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv 2000; 51: 27-31.
7. Fokkema ML, Vlaar PJ, Vogelzang M et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv 2009; 2: 323-329.
8. Vijayalakshmi K, Whittaker VJ, Kunadian B et al. Prospective, randomized controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 2006; 92(9): 1278-1284.
9. Werner GS, Lang K, Kuehnert H et al. Intracoronary Verapamil for Reversal of No-Reflow During Coronary Angioplasty for Acute Myocardial Infarction. Catheter Cardiovasc Interv 2002; 57: 444-451.
10. Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68: 671-6.
11. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. J Am Coll Cardiol 2001; 37: 1335-1343.
12. Wang HJ, Lo PH, Lin JJ, et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injectionin primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004; 63: 171-176.
13. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004; 61: 484-491.
14. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006; 152: 887e9-14.
15. Montalescot G, Antoniucci D, Kastrati A et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007; 28: 443-449.
16. Petronio AS, De Carlo M, Ciabatti N et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005; 150: 1015e1-1015.e9.
17. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in STelevation myocardial infarction trial. Circulation 2008; 118: 49-57.
18. Gu YL, Kampinga MA, Wieringa WG et al. Intracoronary Versus Intravenous Administration of Abciximab in Patients With STSegment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Thrombus Aspiration: The Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial. Circulation 2010; 122: 2709-2717.
19. Thiele H, Wohrle J, Hambrecht R et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomized trial. Lancet 2012; 379; 923-931.
20. Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372: 537-46.
21. Gibson CM, Morrow DA, Murphy SA et al. A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ishemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial. J Am Coll Cardiol 2006; 47: 2364-2373.
22. Piana RN, Paik GY, Moscucci M et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1991; 89: 2514-2518.
23. Svilass T, Vlaar P, van der Horst IC, et al. Thrombus Aspiration during Primary Percutaneous Coronary Intervention. N Engl J Med 2008; 358: 557-67.
24. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008; 371: 1915-20.
25. Migliorini A, Stabile A, Rodriguez A et al, JETSTENT Investigators. Comparison of Angiojet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting With Direct Stenting Alone in Patients with Acute Myocardial Infarction The JETSTENT Trial. J Am Coll Cardiol 2010; 56: 1298-306.
26. Dangas G, Stone GW, Weinberg MD, et al., EMERALD Investigators. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). AmHeart J 2008; 155: 1090-6.
27. Kelbaek H, Terkelsen CJ, Helqvist S, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008; 51: 899-905.
28. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008; 29: 2989-3001.
29. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002; 105: 1285-90.
30. Elbaz M, Mokhtar E, Khalife K et al. Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) study. Am Heart J 2002; 144: e19-24.
31. Loubeyre C, Morice M, Lefevre T et al. A Randomized Comparison of Direct Stenting With Conventional Stent Implantation in Selected Patients With Acute Myocardial Infarction. J Am Coll Cardiol 2002; 39: 15-21.
32. Wilson W and Eccleston D. How to Manage No Reflow Phenomenon with Local Drug Delivery via a Rapid Exchange Catheter. Catheter Cardiovasc Interv 2011; 77: 217-219.